Molly M Shores1, Mary L Biggs, Alice M Arnold, Nicholas L Smith, W T Longstreth, Jorge R Kizer, Calvin H Hirsch, Anne R Cappola, Alvin M Matsumoto. 1. VA Puget Sound Health Care System (M.M.S., N.L.S., A.M.M.), VA Epidemiologic Research and Information Center (N.L.S.), and Geriatric Research, Education, and Clinical Care (A.M.M.), Seattle, Washington 98108; Departments of Psychiatry and Behavioral Sciences (M.M.S.), Biostatistics (M.L.B., A.M.A.), Epidemiology (N.L.S., W.T.L.), Neurology (W.T.L.), and Medicine (A.M.M.), Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, Washington 98195; Department of Medicine and Department of Epidemiology and Population Health (J.R.K.), Albert Einstein College of Medicine, Bronx, New York 10461; Department of Internal Medicine (C.H.H.), Geriatric Medicine, University of California-Davis, Davis, California 95616; and Department of Internal Medicine (A.R.C.), Endocrinology Division, University of Pennsylvania, Philadelphia, Pennsylvania 19104.
Abstract
CONTEXT: Low testosterone (T) is associated with prevalent cardiovascular disease (CVD) and mortality. DHT, a more potent androgen, may also be associated with CVD and mortality, but few studies have examined this. OBJECTIVE: The study objective was to examine whether T and DHT are risk factors for incident CVD and mortality. DESIGN: In a longitudinal cohort study, we evaluated whether total T, calculated free T (cFT), DHT, and calculated free DHT were associated with incident CVD and mortality in men in the Cardiovascular Health Study (mean age 76, range 66-97 years) who were free of CVD at the time of blood collection. MAIN OUTCOME: The main outcomes were incident CVD and all-cause mortality. RESULTS: Among 1032 men followed for a median of 9 years, 436 incident CVD events and 777 deaths occurred. In models adjusted for cardiovascular risk factors, total T and cFT were not associated with incident CVD or all-cause mortality, whereas DHT and calculated free DHT had curvilinear associations with incident CVD (P < .002 and P = .04, respectively) and all-cause mortality (P < .001 for both). CONCLUSIONS: In a cohort of elderly men, DHT and calculated free DHT were associated with incident CVD and all-cause mortality. Further studies are needed to confirm these results and to clarify the underlying physiologic mechanisms.
CONTEXT: Low testosterone (T) is associated with prevalent cardiovascular disease (CVD) and mortality. DHT, a more potent androgen, may also be associated with CVD and mortality, but few studies have examined this. OBJECTIVE: The study objective was to examine whether T and DHT are risk factors for incident CVD and mortality. DESIGN: In a longitudinal cohort study, we evaluated whether total T, calculated free T (cFT), DHT, and calculated free DHT were associated with incident CVD and mortality in men in the Cardiovascular Health Study (mean age 76, range 66-97 years) who were free of CVD at the time of blood collection. MAIN OUTCOME: The main outcomes were incident CVD and all-cause mortality. RESULTS: Among 1032 men followed for a median of 9 years, 436 incident CVD events and 777 deaths occurred. In models adjusted for cardiovascular risk factors, total T and cFT were not associated with incident CVD or all-cause mortality, whereas DHT and calculated free DHT had curvilinear associations with incident CVD (P < .002 and P = .04, respectively) and all-cause mortality (P < .001 for both). CONCLUSIONS: In a cohort of elderly men, DHT and calculated free DHT were associated with incident CVD and all-cause mortality. Further studies are needed to confirm these results and to clarify the underlying physiologic mechanisms.
Authors: Zoë Hyde; Paul E Norman; Leon Flicker; Graeme J Hankey; Osvaldo P Almeida; Kieran A McCaul; S A Paul Chubb; Bu B Yeap Journal: J Clin Endocrinol Metab Date: 2011-10-19 Impact factor: 5.958
Authors: Claes Ohlsson; Elizabeth Barrett-Connor; Shalender Bhasin; Eric Orwoll; Fernand Labrie; Magnus K Karlsson; Osten Ljunggren; Liesbeth Vandenput; Dan Mellström; Asa Tivesten Journal: J Am Coll Cardiol Date: 2011-10-11 Impact factor: 24.094
Authors: Bu B Yeap; Helman Alfonso; S A Paul Chubb; David J Handelsman; Graeme J Hankey; Paul E Norman; Leon Flicker Journal: J Clin Endocrinol Metab Date: 2012-09-13 Impact factor: 5.958
Authors: Robin Haring; Sebastian E Baumeister; Henry Völzke; Marcus Dörr; Stephan B Felix; Heyo K Kroemer; Matthias Nauck; Henri Wallaschofski Journal: Eur J Cardiovasc Prev Rehabil Date: 2011-02
Authors: Catherine Kim; Ana C Ricardo; Edward J Boyko; Costas A Christophi; Marinella Temprosa; Karol E Watson; Xavier Pi-Sunyer; Rita R Kalyani Journal: J Clin Endocrinol Metab Date: 2019-04-01 Impact factor: 5.958
Authors: Ronald S Swerdloff; Robert E Dudley; Stephanie T Page; Christina Wang; Wael A Salameh Journal: Endocr Rev Date: 2017-06-01 Impact factor: 19.871
Authors: Katherine E Joyce; Mary L Biggs; Luc Djoussé; Joachim H Ix; Jorge R Kizer; David S Siscovick; Molly M Shores; Alvin M Matsumoto; Kenneth J Mukamal Journal: J Clin Endocrinol Metab Date: 2017-01-01 Impact factor: 5.958
Authors: Monique S Tanna; Arthur Schwartzbard; Jeffery S Berger; Joseph Alukal; Howard Weintraub Journal: Curr Atheroscler Rep Date: 2015-03 Impact factor: 5.113
Authors: M Reza Sadaie; Mehdi Farhoudi; Masumeh Zamanlu; Nasser Aghamohammadzadeh; Atieh Amouzegar; Robert E Rosenbaum; Gary A Thomas Journal: Ther Adv Drug Saf Date: 2018-05-08